GlassScriptPhysician profile
Carrie Smith
NPI 1043617285
$1,539.66
in general payments reported to CMS, 2019-2025
15 companies · $607 in 2025
The $607 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $78.10 · 2021: $105 · 2022: $249 · 2023: $156 · 2024: $233 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $270.27 | 2023-2025 | |
| Alcon Vision LLC | $254.85 | 2019-2025 | Rocklatan, Eysuvis |
| New World Medical,INC. | $233.86 | 2022-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Via360 |
| Oyster Point Pharma, INC. | $172.29 | 2023-2025 | Tyrvaya |
| Abbvie INC. | $137.45 | 2024-2025 | |
| Allergan, INC. | $74.32 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $73.62 | 2019-2021 | |
| Sight Sciences, INC. | $66.39 | 2024 | Omni Surgical System |
| Dompe US, INC. | $58.13 | 2022-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $55.33 | 2024 | Xiidra |
| Harrow Eye, LLC | $54.66 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $45.80 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $17.45 | 2020 | |
| Sun Pharmaceutical Industries INC. | $13.76 | 2024 | |
| Novartis Pharmaceuticals Corporation | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.